Position
Squarepoint Ops LLC in Corvus Pharmaceuticals, Inc.
Back to the book · All holders of CRVS
Estimated mark uses implied 13F prices (value ÷ shares). Adds are treated as happening at this quarter’s mark; cuts at last quarter’s. Share jumps can be splits, not buys. This is not realized P&L.
Latest estimated mark $726.4K$7.70 → $14.63
| Quarter | Shares | Value | Implied px | Est. mark | Flow | Weight |
|---|---|---|---|---|---|---|
| Q4 2025 | 104.8K | $807.1K | — | — | — | 0.0% |
| Q1 2026 | 123.9K | $1.81M | $14.63 | $726.4K | $279.1K | 0.0% |